Skip to main content
Premium Trial:

Request an Annual Quote

Gene42, SeqOne Partner for Rare Disease Diagnosis

NEW YORK (GenomeWeb) – Startups in Canada and France are combining their genomic analysis and machine learning technology in pursuit of faster, more accurate diagnoses of rare conditions.

Toronto-based Gene42, maker of software that supports precision medicine programs, is partnering with SeqOne, a French developer of a genome analysis platform, to augment gene sequences with phenotypic data from clinical encounters. This collaboration, the companies said today, will address the estimated 80 percent of rare diseases with genetic causes.

Gene42 makes PhenoTips, software that helps clinicians capture and standardize phenotypic information at the point of care. SeqOne's platform can run phenotypes through its machine learning engine to help pinpoint the gene responsible for an otherwise undiagnosed condition.

"The collaboration between SeqOne and PhenoTips creates the opportunity to accurately diagnose more patients in a shorter period of time," SeqOne CEO Nicolas Philippe said in a statement. His company is a spinout of AxLR SATT, a tech incubator in Montpellier, France.

"Capturing the doctor's medical observations in a standardized way makes it much easier to interpret the patient’s genome," added Gene42 CEO Orion Buske.

The companies said that they ran a pilot study in France in which the combination of PhenoTips and SeqOne "significantly" improved diagnostic yield and shortened interpretation time in a group of patients with rare diseases. They did not provide any data, but said they were organizing a larger and broader study to confirm the results.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.